Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial
Journal of the American Heart Association · 02.09.2025 · 14 (17)
DOI: 10.1161/jaha.124.041190 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of the American Heart Association, erschienen am 02.09.2025. Verfasst von Gregory P Geba und 14 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc. Tarrytown NY USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable heterozygous familial hypercholesterolemia (HeFH) or type III hyperlipoproteinemia (T3HLP).
Methods
Patients had clinical HeFH if baseline low‐density lipoprotein cholesterol was ≥250 mg/dL and the qualifying acute coronary syndrome event occurred before age 55 (men) or 60 years (women), or if baseline low‐density lipoprotein cholesterol was ≥330 mg/dL. Patients had T3HLP if the ratio, validated using the UK Biobank database, of non–high‐density lipoprotein cholesterol/apolipoprotein B was >2.6. Genetic variation affecting low‐density lipoprotein cholesterol levels (HeFH) and APOE genotypes (T3HLP) was assessed in a pharmacogenomics subgroup.
Results
In total, 5.8% of patients from ODYSSEY OUTCOMES and 5.9% from the pharmacogenomics subgroup qualified as having clinical HeFH. In the pharmacogenomics subgroup, 295 patients (2.5%) had genetically confirmed HeFH; 45.8% also qualified as having clinical HeFH. Lipid responses and clinical benefits of alirocumab were similar in all patients with or without HeFH. In the ODYSSEY OUTCOMES cohort, 30 of 18 924 patients (0.16%) were identified as having T3HLP. The pharmacogenomics subgroup included 13 of these 30 patients, of whom 7 (53.8%) were APOE2/2 homozygotes. Lipid responses to alirocumab in patients with T3HLP were comparable with those in the general population. In those with genetic dyslipidemia, adverse event incidence was similar to the overall group.
Conclusions
In ODYSSEY OUTCOMES, individuals with HeFH were common while those with T3HLP were rare. In their lipid responses, carriers of both conditions benefited from alirocumab. Registration URL: https://clinicaltrials.gov ; Unique identifier: NCT01663402.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc. Tarrytown NY USA.
- Section of Cardiovascular Medicine, Department of Internal Medicine Wake Forest School of Medicine Winston-Salem NC USA.
- Division of Cardiovascular Disease University of Alabama at Birmingham Birmingham AL USA.
- Mount Sinai Fuster Heart Hospital Icahn School of Medicine at Mount Sinai New York NY USA.
- CPC Clinical Research and Division of Cardiology University of Colorado School of Medicine Aurora CO USA.
- State University of New York Downstate Health Sciences University Brooklyn NY USA.
ORCID-Profile: Kusha A Mohammadi, Amy Damask, Charles Paulding, Robert Pordy, Garen Manvelian, Michael D Shapiro, Vera A Bittner, Deepak L Bhatt, Michael Szarek, Gregory G Schwartz, Ph Gabriel Steg, Sergio Fazio
Zitieren
APA
Geba, G. P., Mohammadi, K. A., Damask, A., Paulding, C., Lotta, L. A., Hindy, G., Pordy, R., Manvelian, G., Shapiro, M. D., Bittner, V. A., Bhatt, D. L., Szarek, M., Schwartz, G. G., Steg, P. G., & Fazio, S. (2025). Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association, 14(17). https://doi.org/10.1161/jaha.124.041190
Vancouver
Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, et al. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association. 2025;14(17). doi:10.1161/jaha.124.041190
BibTeX
@article{Geba2025,
author = {Geba, Gregory P and Mohammadi, Kusha A and Damask, Amy and Paulding, Charles and Lotta, Luca A and Hindy, George and Pordy, Robert and Manvelian, Garen and Shapiro, Michael D and Bittner, Vera A and Bhatt, Deepak L and Szarek, Michael and Schwartz, Gregory G and Steg, Ph Gabriel and Fazio, Sergio},
title = {Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {17},
doi = {10.1161/jaha.124.041190}
}
EUVIMED